The uses and abuses of systematic reviews: the case of ivermectin in Covid-19

*Edmund J Fordham PhD FInstP EurIng

Theresa A Lawrie MBBCh PhD

Katherine MacGilchrist MSc

EbMCsquared, a Community Interest Company Northgate House, Upper Borough Walls, Bath BA1 1RG, UK

Andrew Bryant MSc

Population Health Sciences Institute, Newcastle University Baddiley-Clark Building, Richardson Road, Newcastle upon Tyne NE2 4AX, UK

*Corresponding author.

Address: EbMCsquared CIC Northgate House, Upper Borough Walls, Bath BA1 1RG, UK

Word count: 2839 words excl Refs

2 Tables; 2 Figures

55 references

Background

A recent Cochrane review¹ of ivermectin for the treatment and prevention of Covid-19 stands in contrast to the world-first PRISMA guidelines² systematic review and meta-analysis by Bryant *et al.*³ (hereinafter "Bryant"), which is criticised in the review with further commentary elsewhere⁴. We review here the approach of Popp *et al.*¹ (hereinafter "Popp").

Ivermectin⁵, a WHO Essential Medicine⁶ of negligible cost⁷ and outstanding safety record⁸⁻¹³ has attracted significant attention for its potential use both in treatment and in the prevention of Covid-19, from its known anti-viral effect over a wide class of RNA viruses¹⁴ and specific action¹⁵ *in vitro* against SARS-CoV-2. These initial reports were bolstered by multiple reports¹⁶ of efficacy at all stages of the Covid-19 illness (from prophylaxis through to critical care¹⁷), *in vitro*¹⁸ and *in silico*^{19,20,21} studies of its likely modes of action, clinical experience reports from multiple contexts²², population-level case studies²³, retrospective observational studies²⁴, through to randomised controlled clinical trials³ (RCTs). These reports occupy all levels of the so-called "Evidence Quality Pyramid" in the doctrines of Evidence-Based Medicine.

Systematic Reviews (SRs) and Meta-Analyses (MAs) occupy, in theory, the summit of the pyramid, and are considered the premier quality of evidence by Health Regulatory Authorities (HRAs) and for clinical practice guidelines by national and international health services. However, though SRs and MAs are carried out to identify, qualify or avoid the worst aspects of reporting bias, excluding all other evidence can become itself a powerful source of bias.

The Cochrane organisation²⁵ is dedicated to the development of a library of SRs, confined to the evidence. Cochrane SRs are traditionally conducted by volunteer reviewers, reducing the potential for financial conflicts of interest. Advocacy is not properly part of a SR but of processes such as DECIDE²⁶ in which other stakeholders including public health professionals and patients should be involved. Cochrane has a tradition of accuracy, objectivity and attention to reliability through systematised but necessarily subjective criteria. Similar criteria are more generally available through the guidelines of the PRISMA Working Group², followed in Bryant³.

However, SR methodologies are capable of abuse in respect of (i) choice of inclusion criteria (ii) choice of outcome measures, comparisons and analyses (iii) the subjectivity inevitable in Risk of Bias assessments, even when codified procedures and criteria are observed. We analyse these choices in Popp¹.

The Cochrane Review of Popp¹: synopsis

The stated objectives are to assess efficacy and safety of ivermectin compared to: no treatment, placebo, "standard of care" (SoC) or any "proven" intervention. The analyses compare hospitalised patients and outpatients separately, without pooling of data. The objectives also included the assessment of *prevention* of Covid-19 infection with ivermectin. The stated intention is "to provide a complete evidence profile".

The inclusion criteria were restricted to randomised trials (RCTs), and effectively excluded combination therapies by a requirement for co-interventions to be identical in both arms. Comparators held to be "unproven" were also excluded, as were groups with diagnoses without confirmation by PCR or antigen tests. Outcome measures had prespecified time-points; mortality up to 28 days, and laboratory-confirmed infection at 14 days.

Only studies considered at low RoB or "some concerns" were included in the "primary" analyses; high RoB analyses are reported in "secondary" analyses and regarded as sensitivity analyses. Primary comparisons are summarised in Table 1 with the secondary comparisons for the prophylaxis comparison, where mortality at 28 days was held to be primary and the more relevant symptomatic infection is secondary.

These analyses concentrate on mortality, improvement (to discharge or resolution), deterioration (to need for mechanical ventilation, or need for oxygen or other respiratory support), and Covid-19 infection. Adverse events are compared in addition though a SR of limited scope cannot supersede the extensive pharmacovigilance⁸ already conducted over literally billions²⁷ of ivermectin treatments. Table 1 also shows the total number of patients for each comparison, with the number of events, as a rough indicator the statistical power in each. Very few are actually meta-analyses, because in the majority only a single study is included. Those that do pool data comprise just two studies each.

Unsupported assertions

The background contains unsupported assertions, e.g. that only Non-Pharmaceutical Interventions (NPIs) are available to control infection, whilst exhibiting in Analysis 3.1 a single prophylaxis trial of strong effect and narrow confidence intervals. It is claimed that "serious adverse events (SAE) including vision problems, neurotoxicity and liver damage can occur", though the cited source²⁸ contains no such reports. Moreover the considerable literature⁸⁻¹³ on safety is ignored. Professor Chris Whitty (Chief Medical Officer for England), has himself stated⁹: "The drug has proven to be safe. Doses up to 10 times¹⁰ the approved limit [200 mcg/kg] are well tolerated by healthy volunteers. Adverse reactions are few and usually mild".

The review of (potential) mechanisms of action rehearses an outdated objection that whilst lvermectin slows the reproduction¹⁵ of SARS-CoV-2, "such effects would need major doses [e.g.²⁹] in humans". This conjecture ignores other pharmacokinetic modelling³⁰, the absence of a full immune response in the *in vitro* culture²² and has long been falsified by the results of trials and clinical experience worldwide¹⁶, at 1 – 3 times the anti-parasitic dose³¹. The sole mechanism considered is the blocking of nuclear import of viral proteins by interaction with the Importin $\alpha/\beta 1$ hetero-dimer¹⁸; routinely cited in early reports, this conjecture has long been extended by findings on its anti-inflammatory properties¹⁷ and multiple *in silico* models of its likely interference with critical viral replication enzymes¹⁹⁻²¹ and blocking of the spike protein / ACE2 interaction²⁰.

Inconsistencies in design

Though denigrating Bryant³ as a "bowl of colourful fruit salad"⁴, Popp¹ is inconsistent regarding (potentially) active comparators. They state that hydroxychloroquine "does not work" for covid-19, yet excluded trials with comparators including hydroxychloroquine, a drug they hold to be inactive, effectively placebo (which would be included). Conversely, remdesivir is asserted as an "eligible active comparator" for future updates (though latest evidence³² reports "no clinical benefit"). There is no logic in mixing inactive controls with "deemed-active" ones, whilst rejecting "unapproved" controls declared to be inactive. "HRA approval" and "clinical demonstration" are sadly not the same thing, and HRA policies on SoC vary internationally. Gorial³³ reports that hydroxychloroquine was an Iraqi SoC for

Covid-19, creating an inclusion conflict, had Gorial³³ been a RCT. Hashim³⁴ states that azithromycin was also an Iraqi SoC. Babalola³⁵ is excluded, though the lopinavir/ritonavir comparator was at the time a SoC in Nigeria.

The design in Popp¹ is consistent only in rejecting "unapproved" interventions but including "approved" ones, irrespective of actual efficacy. Popp¹ thus mixes clinical evidence with HRA policies that may not be sound, or even consistent internationally, and encompasses additional controversies e.g. regarding hydroxychloroquine, or remdesivir³². Yet the evidence does not change even if HRA policy does. A research design including politically-driven HRA policies is certain to corrupt a search for objective evidence.

Similarly, the exclusion of combination therapies (e.g. ivermectin-doxycycline) if the adjunct was not present in the control, is to exclude rationally-designed combination therapies (e.g. ZIVERDOX³⁶, I-MASK+³¹, or SMDT^{37,38}) that are in reality the norm among clinicians using ivermectin with success.

The pragmatic approach in Bryant³, in contrast, stated a clear comparison of "ivermectin" against "no ivermectin" and makes no judgments about the efficacy of any other drugs. In regard to potentially-active comparators, reflection should show that any bias is conservatively *against* ivermectin; efficacy will be understated, not overstated, with respect to controls (Figure 1). Unsuspected active agents in ivermectin combination therapies might of course contribute bias the other way, but could only bias a meta-analysis toward an illusory conclusion of ivermectin efficacy if the same adjunct were dominant among the studies or patients in the meta-analysis. The only conflict then requiring resolution would be between an effective "Adjunct X" (ivermectin presumed ineffective) and synergy between the two. Either way, an effective therapy would have been demonstrated.

The fruit-salad analogy may in fact be helpful. If the outcome were the cure of scurvy, stronger results would be expected comparing a diet of oranges to boiled rice, than if the comparator were a fruit salad of unspecified composition. Only if all comparators were equally active would meta-analyses fail to demonstrate the value of oranges for scurvy. Any bias would understate, not overstate, their value. Similarly, if the diet of oranges were in some studies combined with grapefruit, eighteenth-century systematic reviewers might argue that the effect of grapefruit was not discriminated, but only if all studies included

grapefruit could meta-analysis fail to identify the efficacy of oranges, pointing only to the combination.

Specifically in Bryant³, the only candidate adjunct (cited in Popp¹ as grounds for exclusion) is doxycycline, which contributed three included studies^{34,50,51} coming nowhere near dominance in the Bryant³ meta-analysis.

Popp¹ has a requirement for PCR or antigen testing to confirm a diagnosis, though without any examination of their reliability, and unavailable in many of the earlier studies or in resource-limited situations. This criterion would have excluded the RECOVERY trial of dexamethasone³⁹, which nevertheless led to the adoption of corticosteroids as a SoC, and the resulting inclusion of dexamethasone as a "proven" comparator in the review design¹.

Fragmentation

The inclusion policies thus excluded much of the available trials data. Pre-defined (and essentially arbitrary) time-points for outcome measures (28-day mortality, infection within 14 days) resulted in further exclusions. High RoB studies were rejected for "primary" analyses. After multiple exclusions of available trial evidence, Popp¹ performs a final fragmentation of the data by analysing inpatient and outpatient data as separate comparisons, though the patients had the same disease and hospitalisation criteria vary considerably according to local resource constraints.

The overall consequence in Popp¹ is illustrated schematically in Figure 2. The number of trials and participants was minimal for each "analysis". Actual meta-analyses are few; many comparisons reduce to a single study so that no meta-analysis is possible. This reduces their "systematic review", though bulky, largely to a bibliography with synopsis of results.

Fragmentation by review design defeats the whole purpose of meta-analysis.

A "complete evidence profile" ?

Popp¹ claims to provide a "complete evidence profile" but excludes most of the available evidence, available trials not conforming to their own ideal specification.

They also exclude several important confounder-adjusted observational trials^{24,33,40}. There is little basis for such exclusion, as shown exhaustively in another Cochrane Review⁴¹. Randomisation is no guarantee that unmeasured risk factors are balanced between treatment arms, especially in small trials, where the alleged superiority of randomisation may be illusory. Four trials^{7,42-44}, with only 32 – 72 participants each, were included in Popp¹, but reported no risk factors, and were too small for randomisation to be have been a reliable equaliser of confounders. Against these inclusions, exclusion of the early ICON study²⁴ (with 196 participants even in its matched subset) is inconsistent with the goal of a "complete evidence profile".

Though Bryant³ is aligned with Popp¹ in a restriction to RCTs, Bryant³ does not claim to present a "complete evidence profile", and indeed we would argue that it does not. The protocol choice in Bryant³ was governed by standards typically expected by HRAs, to show the strength of the evidence in favour of ivermectin, even in the face of a restriction to RCTs.

A "complete evidence profile" requires consideration of other evidence in the "evidence quality pyramid", including confounder-adjusted observational evidence^{24,40}, the population-scale case studies^{16,23}, and the evidence of clinicians reporting successful interventions with ivermectin-based therapies³⁶. These are typically under-reported in the primary literature precisely because their experience is so often acquired in crisis situations⁴⁵.

Popp¹ claims the virtue, but prevents its realisation by design.

The mortality outcome

We illustrate the inadequacies in Popp¹ by reference to the "headline" inpatient mortality outcome. Does ivermectin save lives?

Results from Popp¹ in Table 2 are compared with the findings of the landmark ICON study²⁴, a confounder-matched retrospective study, those in Bryant³, and the WHO⁴⁶. The Popp¹ meta-analysis (to June 2021) recognises just two small inpatient trials (73 and 112 participants respectively). This is still smaller than even the matched cohort in ICON (196 patients, 280 overall) available a full year earlier, showing a clear mortality benefit, quoting p = 0.045. Popp¹ thus exhibits smaller and poorer-quality data for in-patient mortality than already available more than a year earlier. Even including the outpatient analysis in Popp¹ (a single death in 422 patients, most from the widely-criticised^{48,23} Lopez-Medina study⁴⁹) the Popp¹ evidence is still far smaller than the WHO guideline⁴⁶ from 1419 participants, which though deprecating ivermectin nevertheless quotes a mortality Odds Ratio of 0.19 with narrow Confidence Intervals. Bryant³ covers 2038 patients (even after the removal of a disputed study⁴⁷).

Yet in the face of far more extensive evidence that ivermectin does indeed save lives, Popp¹ contrives the plain language summary: "we don't know whether ivermectin leads to more or fewer deaths".

Summary

Defects in Popp¹ thus include:

- unsupported assertions of adverse reactions to ivermectin, and the outdated claim that unsafe dosing would be needed to be effective;
- 2. a demand for PCR or antigen testing, without analysis of reliability and not universally available even in developed countries at the start of the pandemic;
- contradictions in the exclusion criteria, including placebo and approved SoC comparators, but rejecting hydroxychloroquine, though held to be ineffective (and an approved SoC in some jurisdictions);
- 4. inclusion of "deemed active" comparators whilst excluding "potentially active" ones;
- 5. exclusion of combination therapies, though the norm among practising clinicians;
- 6. the rejection of other than RCTs when the objective is a "complete evidence profile";
- 7. arbitrary time-points for outcome measures, excluding non-compliant trials;
- 8. fragmentation of data by location of care under varying hospitalisation criteria;
- 9. the resulting focus on a small fraction of the available clinical evidence, with most comparisons based on single studies with no meta-analysis possible;
- a resulting inpatient mortality comparison with fewer patients than a June 2020 confounder-matched study;
- no conclusion on the headline mortality outcome, when multiple lines of evidence from elsewhere (including the WHO⁴⁶) point to significant mortality advantage.

What has driven most of the exclusions in Popp¹ are the criteria excluding other than "approved" drugs, with time-point or testing specifications that existing data happens not to satisfy. Refusal to look inevitably finds little.

Conclusion

In designing any SR, one does need to set criteria so that studies are sufficiently homogeneous to make valid statistical comparisons. However the criteria cannot be so narrow as to leave too few data, or data that cannot be generalised from. There is an inevitable tension between statistical purity, and retaining data and clinical relevance; an instance of the eternal struggle between simplicity and truth. By discarding information to preserve purity, we end up communicating untruth; conversely if we abandon all comparability requirements then our message may get lost in confusion. Systematic reviewers must ask themselves whether they have struck the right balance for a particular research question, having regard to the context within which the question has arisen.

Globally we need to identify cheap, safe and effective therapeutics, quickly, so that Covid-19 patients are not left without *prompt* treatment. Using repurposed medicines with established safety profiles is a pragmatic public health strategy. "We call on public health authorities to authorize treatments with known low-risk and possible benefit for outpatients"⁵².

The approach in Popp¹, demanding compliance with design criteria that few existing studies satisfy, offers no insight into important research questions in a health emergency requiring rapid decision-making. Though considerable evidence exists, heterogeneity results in most of it being rejected. Popp¹ should (i) reconsider their balance between statistical purity and delivering clinical relevance, (ii) consider the impact of their selection criteria on their conclusions and (iii) re-consider those criteria (and their search strings) prior to running the planned future updates.

We affirm the pragmatic approach in Bryant³, which was designed precisely to expose key clinical effects from existing trials data, having regard to the manifest urgency. Sensitivity analyses⁵³ already show that the headline mortality and prophylaxis effects are sustained, and a Bayesian analysis allowing causal hypotheses to be ranked on a probability basis shows that the hypothesis of mortality benefit remains supported with high probability even after the exclusion of *two* disputed trials⁵⁴.

Though castigated⁴ for "pooling heterogenous populations comparators and outcomes" this is to a degree required in *any* meta-analysis, and the effects of (i) potentially active comparators and (ii) adjuncts, are readily assessed by simple thought, as outlined above.

Popp¹ adds nothing to the evidence on ivermectin in Covid-19, and indeed deems most of it not to exist, promoting an almost counter-factual impression. Meanwhile, a global health emergency continues, and lives continue to be lost, economies and social fabric are torn apart, whilst a WHO Essential Medicine⁶ of unparalleled safety profile⁸⁻¹³ is withheld by many HRAs, merely because of debates over its quantitative metrics of effect.

The responsible physician knows that "first do no harm" does not mean: "do nothing". Doing nothing, especially for the high-risk patient, is unacceptable. It is lethal folly to withhold a safe⁸⁻¹³ medicine that, when viewing the totality of the evidence⁵⁵, shows great promise at negligible cost. Such policies effectively deny to dedicated clinicians the ability to practice medicine. It is high time those policies were ended.

References

[1] Popp M, Stegemann M, Metzendorf M-I, *et al.* Ivermectin for preventing and treating covid-19. Cochrane Database Syst Rev 2021;7:CD015017. doi: 10.1002/14651858.CD015017.pub2
pmid: http://www.ncbi.nlm.nih.gov/pubmed/34318930

[2] Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021;372. doi: 10.1136/bmj.n71. Accessed 22 July 2021.

[3] Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for prevention and treatment of covid-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. *Am J Therap* 2021; **28**, e434–460. doi:10.1097/MJT.00000000001402

[4] Popp M, Kranke P, Meybohm P, *et al*. Evidence on the efficacy of ivermectin for covid-19: another story of apples and oranges. *BMJ Evidence-Based Medicine* Published Online First: 20 August 2021. doi: 10.1136/bmjebm-2021-111791

[5] Crump, A. (2017). Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations. *The Journal of Antibiotics*, **70**, 495-505. doi: 10.1038/ja.2017.11

[6] World Health Organisation (2019). Model List of Essential Medicines, 21st List. https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf

[7] Ahmed, S., Karim, M. M., Ross, A. G., Hossain, M. S., Clemens, J. D., Sumiya, M. K. *et al.* (2021). A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. *International Journal of Infectious Diseases*, **103**, 214-216. doi: 10.1016/j.ijid.2020.11.191

[8] WHO (2021). VigiAccess, WHO Collaborating Centre for International Drug Monitoring (Uppsala) www.vigiaccess.com

[9] Chaccour, C., Lines, J. & Whitty, C. J. M. (2010). Effect of Ivermectin on Anopheles gambiae Mosquitoes Fed on Humans: The Potential of Oral Insecticides in Malaria Control. *Journal of Infectious Diseases*, **202**, 113-116. doi: 10.1086/653208

[10] Guzzo, C., Furtek, C., Porras, A., Chen, C., Tipping, R., Clineschmidt, C., *et al.* (2002). Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects. *Journal of Clinical Pharmacology*, **42**, 1122-1133. doi: https://doi.org/10.1177/009127002237994

[11] Kircik, L. H., Del Rosso, J. Q., Layton, A. M. & Schauber, J. (2016). Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications. *Journal of Drugs in Dermatology*, **15**, 325-332.

[12] Navarro, M., Camprubí, D., Requena-Méndez, A., Buonfrate, D., Giorli, G., Kamgno, J., Gardon, J., Boussinesq, M., Muñoz, J. & Krolewiecki, A. (2020). Safety of high-dose ivermectin: a systematic review and meta-analysis. *Journal of Antimicrobial Chemotherapy*, **75**, 827-834. doi: https://doi.org/10.1093/jac/dkz524

[13] Descotes, J. (2021) Expert review report: Medical safety of ivermectin. Report to MedinCell SA by ImmunoSafe consultancy, February 2021. Available on request from https://www.medincell.com/ivermectin/

[14] Heidary, F. & Gharebaghi, R. (2020). Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. *The Journal of Antibiotics*, **73**, 593--602. doi: 10.1038/s41429-020-0336-z

[15] Caly, L., Druce, J. D., Catton, M. G., Jans, D. A. & Wagstaff, K. M. (2020). The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Research*, **178**, 104787. doi: https://doi.org/10.1016/j.antiviral.2020.104787

[16] Kory, P., Meduri, G. U., Varon, J., Iglesias, J. & Marik, P. E. (2021). Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. *American Journal of Therapeutics*, **28**, e299-e318. doi: 10.1097/MJT.00000000001377

[17] DiNicolantonio, J. J., Barroso, J. & McCarty, M. (2020). Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. *Open Heart*, **7**, e001350. doi: 10.1136/openhrt-2020-001350

[18] Yang, S. N., Atkinson, S. C., Wang, C., Lee, A., Bogoyevitch, M. A., Borg, N. A. & Jans, D. A. (2020). The broad spectrum antiviral ivermectin targets the host nuclear transport importin $\alpha/\beta 1$ heterodimer. *Antiviral Research*, **177**, 104760. doi: https://doi.org/10.1016/j.antiviral.2020.104760

 [19] Francés-Monerris, A., Garcia-Iriepa, C., Iriepa, I., Hognon, C., Miclot, T., Barone, G., Monari, A. & Marazzi, M. (2020). Has Ivermectin Virus-Directed Effects against SARS-CoV-2?
 Rationalizing the Action of a Potential Multitarget Antiviral Agent., doi: 10.26434/chemrxiv.12782258.v1

[20] Lehrer, S. & Rheinstein, P. H. (2020). Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2. *In Vivo*, **34**, 3023-3026. doi: 10.21873/invivo.12134

[21] Mody, V., Ho, J., Wills, S., Mawri, A., Lawson, L., Ebert, M. C. C. J. C., Fortin, G. M., Rayalam, S. & Taval, S. (2021). Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. *Communications Biology*, **4**, 93-103. doi: 10.1038/s42003-020-01577-x

[22] Yagisawa, M., Foster, P. J., Hanaki, H. & Ōmura, S. (2021). Global trends in clinical studies of ivermectin in Covid-19. *Japanese Journal of Antibiotics*, **74**, 44-95.

[23] Santin, A. D., Scheim, D. E., McCullough, P. A., Yagisawa, M. & Borody, T. J. (2021). Ivermectin: a multifaceted drug of Nobel prize-honored distinction with indicated efficacy against a new global scourge, Covid-19. *New Microbes and New Infections*, 100924. doi: https://doi.org/10.1016/j.nmni.2021.100924

[24] Cepelowicz-Rajter, J., Sherman, M. S., Fatteh, N., Vogel, F., Sacks, J. & Rajter, J.-J. (2020). Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study). *Chest*, **159**, 85-92. doi: 10.1016/j.chest.2020.10.009

[25] Cochrane Gynaecological, Neuro-oncology and Orphan Cancers group (CGNOC) (2021) Our logo tells a story. https://gnoc.cochrane.org/our-logo Accessed 28 September 2021. [26] GRADE-DECIDE (2016). The DECIDE Project, European Commission 7th Framework. https://www.decide-collaboration.eu

[27] Nicolas, P., Maia, M. F., Bassat, Q., Kobylinski, K. C., Monteiro, W. & Rabinovich, N. R. (2020). Safety of oral ivermectin during pregnancy: a systematic review and metaanalysis. *The Lancet Global Health*, 8, E92 - E100. doi: https://doi.org/10.1016/S2214-109X(19)30453-X

[28] González Canga, A., Sahagún Prieto, A. M., Diez Liébana, M. J., Fernández Martínez, N., Sierra Vega, M. & García Vieitez, J. J. (2008). The Pharmacokinetics and Interactions of Ivermectin in Humans---A Mini-review. *The AAPS Journal*, **10**, 42-46. doi: 10.1208/s12248-007-9000-9

[29] Schmith, V. D., Zhou, J. (J. & Lohmer, L. R. (2020). The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. *Clinical Pharmacology and Therapeutics*, **108**, 762-765. doi: https://doi.org/10.1002/cpt.1889

[30] Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R., Curley, P. *et al.* (2020). Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. *Clinical Pharmacology and Therapeutics*, **108**, 775-790. doi: 10.1002/cpt.1909

[31] Front-Line Covid-19 Critical Care Alliance (2021). The "I-MASK+" Prevention and Early Treatment protocol for Covid-19. https://covid19criticalcare.com/wpcontent/uploads/2020/11/FLCCC-Alliance-I-MASKplus-Protocol-ENGLISH.pdf Accessed 3 September 2021

[32] Ader, F., Bouscambert-Duchamp, M., Hites, M., Peiffer-Smadja, N., Poissy, J., Belhadi, D., *et al.* (2021). Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. *Lancet Infectious Diseases*, doi: 10.1016/S1473-3099(21)00485-0

[33] Gorial, F. I., Mashhadani, S., Sayaly, H. M., Dakhil, B. D., AlMashhadani, M. M., Aliabory, A. M., *et al.* (2020). Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial). *medRxiv* preprint doi: 10.1101/2020.07.07.20145979

[34] Hashim, H. A., Maulood, M. F., Rasheed, A. M., Fatak, D. F., Kabah, K. K. & Abdulamir, A.
S. (2020). Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. *medRxiv* preprint doi: 10.1101/2020.10.26.20219345

[35] Babalola, O., Bode, C., Ajayi, A., Alakaloko, F., Akase, I., Otrofanowei, E., *et al.* (2021). Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos. *QJM: An International Journal of Medicine*, doi: 10.1093/qjmed/hcab035

[36] Hazan, S., Dave, S., Gunaratne, A. W., Dolai, S., Clancy, R. L., McCullough, P. A. & Borody, T. J. (2021). Effectiveness of Ivermectin-Based Multidrug Therapy in Severe Hypoxic Ambulatory COVID-19 Patients. *medRxiv* preprint, doi: 10.1101/2021.07.06.21259924

[37] McCullough, P. A., Alexander, P. E., Armstrong, R., Arvinte, C., Bain, A. F., Bartlett, R. P., *et al.* (2020). Multifaceted highly targeted sequential multidrug treatment of early

ambulatory high-risk SARS-CoV-2 infection (COVID-19). *Reviews in Cardiovascular Medicine*, **21**, 517. doi: 10.31083/j.rcm.2020.04.264

[38] Procter, B. C., Ross, C., Pickard, V., Smith, E., Hanson, C. & McCullough, P. A. (2020).
Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. *Reviews in Cardiovascular Medicine*, **21**, 611. doi: 10.31083/j.rcm.2020.04.260

[39] Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., *et al.* (2020). Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. *New England Journal of Medicine*, doi: 10.1056/NEJMoa2021436

[40] Behera, P., Patro, B. K., Singh, A. K., Chandanshive, P. D., Ravikumar S.R., Pradhan, S. K. *et al.* (2020). Role of ivermectin in the prevention of Covid-19 infection among healthcare workers in India: A matched case-control study. *PloS ONE*, **16**, e0247163. doi: 10.1371/journal.pone.0247163

[41] Anglemyer, A., Horvath, H. & Bero, L. (2014). Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. *Cochrane Database of Systematic Reviews*, doi: 10.1002/14651858.MR000034.pub2

[42] Kishoria, N., Mathur, S. L., Parmar, V., Kaur, R. J., Agarwal, H., Parihar, B. S. & Verma, S. (2020). Ivermectin as adjuvant to hydroxychloroquine in patients resistant to standard treatment for SARS-CoV-2. Results of an open-label randomised clinical study. *Paripex - Indian Journal Of Research*, **9**, 50-53. doi: 10.36106/paripex/4801859

[43] Podder, C., Chowdhury, N., Sina, M. & Haque, W. (2020). Outcome of ivermectin treated mild to moderate Covid-19 cases: a single-centre, open-label, randomised controlled study. *IMC Journal of Medical Science*, **14**. doi: 10.3329/imcjms.v14i2.52826

[44] Pott-Junior, H., Bastos Paoliello, M. M., Miguel, A. Q. C., da Cunha, A. F., de Melo Freire, C. C., Neves, F. F., *et al.* (2021). Use of ivermectin in the treatment of Covid-19: A pilot trial. *Toxicology Reports*, **8**, 505-510. doi: 10.1016/j.toxrep.2021.03.003

[45] Stone, J. (2021). How many more must die? Presentation to Malaysian Alliance for Effective Covid Control (MAECC), 17 July 2021. Available at https://www.bitchute.com/video/GtxN5If05vHs/

[46] World Health Organisation (2021). Therapeutics and COVID-19: living guideline. World Health Organisation, 31 March 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.1

[47] Elgazzar, A., Hany, B., Youssef, S. A., Hafez, M., Moussa, H. & Eltaweel, A. (2020). Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic. *Research Square* preprint (withdrawn). doi: 10.21203/rs.3.rs-100956/v2

[48] Scheim, D., Hibberd, J. A. & Chamie-Quintero, J. (2021). Protocol violations in López-Medina et al.: 38 switched ivermectin (IVM) and placebo doses, failure of blinding, widespread IVM sales OTC in Cali, and nearly identical AEs for the IVM and control groups. *Open Science Foundation* preprint. doi: 10.31219/osf.io/u7ewz [49] López-Medina, E., López, P. & Hurtado, I. C. (2021). Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild Covid-19: A Randomized Clinical Trial. *Journal of the American Medical Association*, doi: 10.1001/jama.2021.3071

[50] Mahmud, R., Rahman, M. M., Alam, I., Ahmed, K. G. U., Kabir, A. H., Sayeed, S. J. B., *et al.* (2021). Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. *Journal of International Medical Research*, **49**, 030006052110135. doi: 10.1177/03000605211013550

[51] Chowdhury, A. T. M. M., Shahbaz, M., Karim, M. R., Islam, J., Guo, D. & He, S. (2020). A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients. *Research Square* preprint, doi: 10.21203/rs.3.rs-38896/v1

[52] Ngo, B. T., Marik, P., Kory, P., Shapiro, L., Thomadsen, R., Iglesias, J. *et al.* (2021). The time to offer treatments for COVID-19. *Expert Opinion on Investigational Drugs*, **30**, 505-518. doi: 10.1080/13543784.2021.1901883

[53] Bryant, A., Lawrie, T. A. & Fordham, E. J. (2021). Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American Journal of Therapeutics, 28, e434-e460, July 2021. *American Journal of Therapeutics*, **28**, e573-e576. doi: 10.1097/MJT.00000000001442

[54] Neil, M. & Fenton, N. (2021). Bayesian Hypothesis Testing and Hierarchical Modeling of Ivermectin Effectiveness. *American Journal of Therapeutics* **28**, e576-e579. doi: 10.1097/MJT.00000000001450

[55] Marik, P. E. *et al.* (2021). Summary of the evidence for ivermectin in Covid-19. FLCCC bulletin. https://covid19criticalcare.com/wp-content/uploads/2021/08/SUMMARY-OF-THE-EVIDENCE-BASE-FINAL.pdf

inpatients	outpatients	prophylaxis	
Mortality	Mortality	Mortality	
(2 studies)	(2 studies)		
185 patients; 14 events	422 patients; 1 event	304 patients; 0 events	
Need for mechanical ventilation	Need for mechanical	Symptomatic Covid-19	
185 patients: 12 events	ventilation		
	398 patients; 1 event	304 patients; 74 events	
Need for oxygen	Need for non-invasive		
	support		
45 patients; 0 events	398 patients; 0 events		
Improvement to discharge	Improvement to		
73 patients: 54 events	resolution		
	398 patients; 246 events		
Adverse events	Adverse events	Adverse events	
	(2 studies)		
152 patients; 20 events	422 patients; 325 events	304 patients; 11 events	
Serious adverse events			
(2 studies)			
207 patients; 1 event			
Admission to ICU	-		
(2 studies)			
143 patients; 13 events			
Duration of hospital stay	-		
45 patients			
Viral clearance at 3, 7, 14 days	-		
(2 studies)			
170 patients; 23, 59 & 26 events			

Table 1. Summary of the primary analyses in Popp¹, with numbers of patients and events shown as a rough indicator of statistical power. Only those analyses marked had more than one study contributing to the comparison. Mortality was considered the "primary analysis" in the prophylaxis question though reporting no deaths; under this heading the more meaningful "infection" outcome is also shown, though considered a "secondary" analysis. Analyses considered secondary in Popp are shown in italics. There were 9 further secondary analyses not shown. In all these, the studies, patients and events are similarly sparse.



Figure 1. (Schematic only). The likely effect of including studies with unsuspected or uncertain active controls in a meta-analysis. There would be a conservative bias against the intervention tested.



Figure 2. Overall effect of the exclusion criteria in Popp¹. The majority of the available evidence is rejected because of non-compliance with a preferred "ideal" trial design.

The data left over for the leading mortality analyses are shown.

	Date available	patients	events	studies	Risk Ratio (OR where stated) [95% Cls]
Popp ¹ (1.1.1, moderate) ^a	July 2021	185	14	2	0.60 [0.14, 2.51]
ICON ²⁴ (inpatients, matched subset) ^b	June 2020	196	37	1	0.54 [0.29 <i>,</i> 1.00]
WHO ^{46, c} (Forest plot, Risk Ratio)	March 2021	915	31	5	0.36 [0.17, 0.75]
WHO ^{46, d} (Summary, Odds Ratio)	March 2021	1419	n/a	7	0.19 {OR} [0.09 <i>,</i> 0.36]
Bryant ^{3,53} (w/o Elgazzar) ^e	July-Sept 2021	2038	93	15	0.51 [0.27, 0.95]

Table 2. Abstract of mortality analyses from Popp¹, the ICON²⁴ study, WHO⁴⁶, and Bryant⁵³. ^aPopp¹ Risk Ratio (RR) quoted in source.

^bICON²⁴ total study size 280 patients; quoted figures for confounder-adjusted cohort only. RR re-calculated from source data (OR reported in source, p=0.045). "Severe" patient subset

is smaller (25 patients) but the mortality advantage yet higher, quoting p<0.002.

^cWHO⁴⁶ RR from Forest plot in "Living Guideline", page 18

^dWHO⁴⁶ OR from summary in "Living Guideline", page 19. Not directly convertible to RR because of insufficient data. All disease severities.

^dBryant⁵³ data excludes Elgazzar⁴⁷. Subgrouped by severity.